Experts spoke about the practice of using Esperavir® and Skyvir® drugs as etiotropic therapy for COVID–19

The drugs Esperavir and Areplivir are included in the current treatment regimens for seasonal acute respiratory viral infections

Promomed Group of Companies has patented the methods of obtaining and using the drug Radamine® Viro

Esperavir® is the best launch of 2021 in the budget sales segment according to IQVIA

Phosphazide is a new drug in the Promomed Group's antiretroviral portfolio

Skyvira® is included in the updated list of medicines for the treatment of COVID-19

Promomed Group of Companies has registered a new antitumor drug for the treatment of common cancers

Promomed's oncological portfolio has been replenished with a new drug for the treatment of common forms of colorectal cancer

Promomed Group of Companies has registered a powerful broad-spectrum antibiotic

Promomed Group of Companies has registered a powerful broad-spectrum antibiotic

Promomed Company has registered a new antitumor drug for the treatment of the most common types of cancer

The advantages of the innovative Brainmax® drug from Promomed Group were discussed by the participants of the Neuroforum

Efavirenz is a new drug for the treatment of HIV infection in the Promomed Group's drug portfolio

Promomed's Modelform® is the winner of the Smartpharma® Awards 2022

Sorafenib is a new drug in Promomed Group's cancer portfolio

Promomed Group's oncological portfolio has been replenished with a new drug for the treatment of blood cancer

Skyvira® is a generation 2.0 anticoid drug

Russian medicine has received an innovative neuroprotector

2

Get the most interesting news and publications first!

Sent successfully!

Pharmacovigilance

Press office

To request a press release or interview, please contact our press office